A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

The experience of Connaught Labs offers lessons for Canada's new Sanofi deal to manufacture vaccines in Canada, and it doesn't appear the government has learned much from it.

A woman, pictured July 20, 2020, walking down Wellington Street in Ottawa. Before COVID-19, industry had shown little interest in developing treatments against coronaviruses. This led many to suggest that we should rethink how we encourage biopharmaceutical innovation for public health emergencies.The Hill Times photograph by Andrew Meade

Opinion

BY MATTHEW HERDER AND SRINIVAS MURTHY

April 19, 2021

The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of deals meant to protect Canada against this, if not future, pandemics. Occupying the grounds of what was once “Connau...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy